Clinical Advances in Hematology & Oncology最新文献_第9页

First-line use of antiangiogenic agents in unresectable hepatocellular carcinoma: a double-edged sword? 抗血管生成药物在不可切除的肝细胞癌中的一线应用：双刃剑？

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-07-01

Aditya Mahadevan, Armon Azizi, Nadine Abi-Jaoudeh, Jennifer Valerin, April Choi, Harry Nguyen, Farshid Dayyani

{"title":"First-line use of antiangiogenic agents in unresectable hepatocellular carcinoma: a double-edged sword?","authors":"Aditya Mahadevan, Armon Azizi, Nadine Abi-Jaoudeh, Jennifer Valerin, April Choi, Harry Nguyen, Farshid Dayyani","doi":"","DOIUrl":"","url":null,"abstract":"Treatment options for hepatocellular carcinoma (HCC), the most prevalent primary liver malignancy, have historically been limited, particularly in unresectable cases with underlying cirrhosis. Initial systemic therapy with antiangiogenic agents, notably vascular endothelial growth factor (VEGF) inhibitors such as sorafenib, showed modest survival gains but lacked durable responses. Subsequent trials with more potent VEGF pathway inhibitors failed to improve overall survival significantly, raising concerns about the long-term utility and potential hepatic and renal toxicities of prolonged VEGF blockade. The advent of immune checkpoint inhibitors (ICIs) marked a paradigm shift. Trial results demonstrating that dual-ICI regimens induced more durable responses and achieved higher long-term survival rates have challenged the prior VEGF-centric therapeutic approach and suggest that early use of dual ICIs may offer a more transformative effect on disease trajectory. Although anti-VEGF therapies remain valuable for initial tumor shrinkage, prolonged use may compromise liver regeneration and worsen portal hypertension. A refined treatment strategy emphasizing VEGF inhibition for a limited duration followed by or combined with ICIs may optimize both efficacy and safety. Future research should focus on identifying predictive biomarkers for ICI response and on developing regimens that maximize long-term survival in unresectable HCC.","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 5","pages":"301-306"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reducing drug toxicity and costs through off-label dosing. 通过超说明书剂量降低药物毒性和成本。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-07-01

Mark J Ratain

引用次数: 0

Is doublet therapy becoming a standard of care in myelofibrosis? 双重治疗正在成为骨髓纤维化的标准治疗吗？

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-07-01

Raajit K Rampal

引用次数: 0

Sequencing antibody-drug conjugates in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. 激素受体阳性her2阴性转移性乳腺癌患者的抗体-药物偶联物测序

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-07-01

Javier Cortés

引用次数: 0

Update on LAG3 and immunotherapy combinations in melanoma. 黑色素瘤中LAG3和免疫联合治疗的最新进展。

IF 1.1